Antengene announces acceptance of IND application in China for ATG-010 (selinexor) in combination with R-GDP (SR-GDP) for the treatment of rrDLBCL in ... Dec 07
Sinovac expects to be able to manufacture 300 million doses annually and aims to complete the construction of a second production facility by the end ... Dec 07
This collaboration, which combines KaliVir's expertise in the development of oncolytic viruses with Astellas' capabilities in advanced drug development... Dec 07
CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma... Dec 07
Results showed that Hemlibra’s safety profile was consistent with previous observations and no new safety signals were observed after the longer follow-up... Dec 07
-Advertisements-